OmniAb is a speculative, cash-burning biotechnology platform whose losses are narrowing and whose recent earnings beats and revenue rebound support the story, but low business quality and binary industry risk keep it from earning a position.
Thesis pillars
- Cash Burn Low Quality↓Deteriorating
- Narrowing Losses Earnings Beats→Stable
- Revenue Rebound Lumpy→Stable
- +2 more pillars — see the Why tab for full reasoning
OmniAb, Inc. (OABI) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Momentum 3.8/10 is below the 5.0 floor at $4.73 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Negative momentum; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.6).
OmniAb, Inc. licenses antibody discovery technology — including its proprietary transgenic OmniRat, OmniChicken, and OmniMouse platforms and AI-powered xPloration screening system — to pharmaceutical, biotech, and academic partners for next-generation therapeutic antibody... Read more
Sell if holding. Momentum 3.8/10 is below the 5.0 floor at $4.73 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Negative momentum; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.6). Chart setup: RSI 53 mid-range, Bollinger mid-band. Score 5.4/10, moderate confidence.
Passes 6/8 gates (favorable risk/reward ratio, clean insider activity, news events none recent, earnings proximity 15d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: speculative.
About OmniAb, Inc.
About OmniAb, Inc.
OmniAb licenses its proprietary transgenic antibody-discovery platform — OmniRat, OmniChicken, OmniMouse, and related technologies — to pharmaceutical, biotech, and academic partners, reporting 107 active partners and 407 active programs as of December 31, 2025, including 27 OmniAb-derived antibodies in clinical development, two under regulatory review, and three approved products. Three partners accounted for 37% of fiscal 2025 revenue, up from 35% in fiscal 2024, while the remaining 27 partners contributed the other 63%.
OmniAb earns revenue through structured platform license agreements that combine upfront or annual technology-access fees, payments for research services, downstream preclinical, IP, clinical, regulatory, and commercial milestones, and royalties on partner product sales, with royalty terms generally running the longer of 10 years from first commercial sale or the last patent expiration covering the antibody. Management expects revenue to be driven mainly by milestones and services in the near term and by royalties over the long term, though the company does not control the clinical development, regulatory strategy, or commercialization of partner programs built on its platform. OmniAb relies on third parties to host its mouse and rat colonies and to supply laboratory equipment and materials, a dependency the 10-K flags as capable of delaying or impairing research and development if those third parties fail to perform satisfactorily. License agreements are typically terminable by partners without penalty on specified notice, though milestone payments and royalties on any OmniAb-derived antibody survive termination.
Show full overview
OmniAb's revenue is more concentrated among a handful of partners than its 107-partner, 407-program headline figures suggest: just three partners generated 37% of fiscal 2025 revenue, up from 35% in fiscal 2024, even as 27 other partners split the remaining 63%. Because license agreements are typically terminable by partners without penalty on specified notice, and OmniAb does not control whether a partner advances, deprioritizes, or discontinues a program, the loss of even one of those top-three relationships could materially affect near-term results — a structural feature of the licensing model that differs from a biotech company's typical single-asset pipeline risk, since OmniAb's exposure is spread across programs but concentrated across paying counterparties.
See also: Healthcare · Biotechnology
From OmniAb, Inc.'s most recent 10-K filing, extracted August 23, 2026.
Recent developments
updated 2026-10-16Recent Developments — OmniAb, Inc.
Latest news
- NEWS OmniAb (OABI) Q2 2026 Earnings Call Transcript - AOL.ca — AOL.ca neutral
- NEWS Truist Financial Maintains OmniAb(OABI.US) With Buy Rating - Moomoo — Moomoo positive
- NEWS OmniAb Leads The Pack Of 3 Intriguing Penny Stocks - Simply Wall Street — Simply Wall Street positive
- NEWS OABI Maintained by Leerink Partners -- Price Target Raised to $1 - GuruFocus — GuruFocus positive
- NEWS OmniAb Is Maintained at Outperform by Leerink Partners - Moomoo — Moomoo positive
Generated 2026-10-16T11:42:17Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMCustomertop three partners37%10-K Item 1A: 'three of our partners accounted for 37% and 35% respectively, of our revenue'
Material Events(8-K, last 90d)
- 2026-07-13Item 5.02LOWAmechi Nwachuku appointed Chief Operating Officer effective July 13, 2026, joining from Thermo Fisher Scientific. New hire, not a departure; routine executive appointment.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Momentum 3.8/10 is below the 5.0 floor at $4.73 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Negative momentum; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.6). Chart setup: RSI 53 mid-range, Bollinger mid-band. Prior stop was $4.40. Score 5.4/10, moderate confidence.
Take-profit target: $7.25 (+53.3% upside). Prior stop was $4.40. Stop-loss: $4.40.
V7 low-quality RISK_OFF penalty: -0.5 (Q=4.6); Negative momentum; Value-trap signals (2/5): Margin compression (op margin -49.5%), Negative free cash flow.
OmniAb, Inc. trades at a P/E of N/A (forward -15.6). TrendMatrix value score: 5.4/10. Verdict: Sell.
13 analysts cover OABI with a consensus score of 4.2/5. Average price target: $8.
What does OmniAb, Inc. do?OmniAb, Inc. licenses antibody discovery technology — including its proprietary transgenic OmniRat, OmniChicken, and...
OmniAb, Inc. licenses antibody discovery technology — including its proprietary transgenic OmniRat, OmniChicken, and OmniMouse platforms and AI-powered xPloration screening system — to pharmaceutical, biotech, and academic partners for next-generation therapeutic antibody discovery. As of December 31, 2025, the company had 107 active partners running 407 active programs, including 27 antibodies in clinical development, two under regulatory review, and three approved partner products.